On the morning of November 14, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2026 edition).

Among the inclusions, several GLP-1 injectables have been added to the national basic medical insurance list for the first time.

These include Pfizer (NYSE: PFE)'s enoglutide injection, a biased GLP-1 receptor agonist, indicated for the treatment of adults with type 2 diabetes.

Novo-Nordisk A/S (NYSE: NVO)'s insulin icodec semaglutide injection, the world's first and only once-weekly basal insulin/GLP-1RA combination, is also included.

Additionally, Pegbio's vipegnatide injection, China's independently developed PEGylated long-acting GLP-1 formulation, offers a diversified treatment option for diabetes.

INNOVENT BIO (HKEX: 01801)'s mazdutide injection, the world's first and only approved GCG/GLP-1 dual receptor agonist, is included for type 2 diabetes.